MedPlus Health Services has announced that one of its subsidiaries has received a seven-day drug license suspension from authorities in Maharashtra. The temporary suspension represents a regulatory compliance issue that will impact the subsidiary's operations in the state.

Financial Impact

The company has estimated the potential revenue loss from this seven-day suspension at ₹3.85 lakhs. This figure represents the expected impact on the subsidiary's business operations during the period when the drug license remains suspended.

Regulatory Compliance

The drug license suspension indicates regulatory compliance issues faced by the subsidiary in Maharashtra. Such suspensions typically occur when pharmaceutical retail operations fail to meet specific regulatory requirements or standards set by state drug control authorities.

The temporary nature of the suspension suggests that the issues identified by regulators may be addressable within the specified timeframe. The company will need to ensure compliance with all regulatory requirements before the license can be reinstated for normal operations.

MedPlus Health Services Limited has informed stock exchanges about a regulatory action affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a subsidiary, received a drug license suspension order from the Assistant Director, Drugs Control Administration, Rangareddy, Telangana.

Regulatory Action Details

The suspension order targets a specific store operated by the subsidiary in Kuntloor, Telangana. The regulatory action was initiated under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Financial Impact

The company has quantified the potential financial impact of this regulatory action. MedPlus estimates a potential revenue loss of Rs 0.42 lacs due to the one-day suspension of the drug license for the affected store.

Compliance Disclosure

This disclosure was made under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also referenced SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, in its regulatory filing.

The information has been made available on the company's website at www.medplusindia.com and will also be accessible on the BSE and NSE websites. Company Secretary & Compliance Officer Manoj Kumar Srivastava signed the disclosure on February 28, 2026.